Nov 5, 2025 | H&P News, M&A
The CDMO landscape is evolving rapidly, with certain segments — such as biologics, cell and gene therapies and advanced aseptic manufacturing — experiencing strong growth, while more traditional small-molecule and generics-focused areas face increasing margin pressure...
Sep 17, 2025 | H&P News, M&A
Basel / Berlin / Rostock, September 2025 – Hoffmann & Partner is pleased to announce that it has advised the shareholders of Nostos Genomics GmbH (“Nostos”) as M&A advisors in the successful acquisition by Limbus Medical Technologies GmbH (“Limbus”). Two...
Jul 24, 2025 | H&P News, M&A
This newsletter provides a comprehensive overview of M&A activity in the healthcare industry across the DACH region, with a particular focus on Switzerland. The analysis covers transactions from 2021 to 2024. At a glance: After a multi-year decline, healthcare...
May 26, 2025 | CFO-Services, H&P News, M&A
Patrick Schacher, CFO Partner, had the opportunity to speak with Dr Paul Senn, CEO of Galvita, about their collaboration at our stand at the Swiss Biotech Days. Galvita AG, based in Basel, specialises in the production of microcapsules (Templated Inverted Particles /...
May 13, 2025 | CFO-Services, Corporate Finance, H&P News, M&A
The Swiss Biotech Days, the global biotech conference for life science professionals, took place at the Congress Center Basel from 5-6 May. We attended for the second time and for our team on site it was once again a great opportunity to meet visitors and other...
